Skip to content

Lumenis UltraPulse Encore

Save device

CO2 Fractional/Ablative · CO2 10600nm fractional + fully ablative (ActiveFX/DeepFX/TotalFX)

Technology: CO2 Fractional Laser

Classification & configurations

Category group: Resurfacing & pigment (ablative, fractional, picosecond, vascular)

Legacy model

At a glance

New-unit reference · older model
Not published
Used asking price
$25k–$55kSource not documented
FDA status
Supplies & recurring costs
See supply and replacement costs below.
View supply details
Sources and verified data on file

Data on file

Recurring consumables
Not verified
FDA
FDA ClearedK022060
Used asking prices
Not verified
  • This panel shows a per-treatment supply cost only when a recorded figure has a dated source.
  • Bottle prices and estimates may still appear under Treatment & running costs.
  • The calculator may include a labeled planning estimate. Review it or enter your own allowance; missing data never means $0.

Figures are reference points, not current offers. Used asking prices are not completed-sale values.

Manufacturer-source documents checked: August 31, 2026

Read FDA-cleared indicationsExact wording from 1 FDA record

K022060 (Lumenis, Inc., 2002)

Lumenis UltraPulse Encore Carbon Dioxide Surgical Lasers (and their delivery accessories) are used to deliver light energy and are indicated for use in surgical applications requiring the ablation, vaporization, excision, incision, and coagulation of soft tissue in medical specialties including: aesthetic (dermatology and plastic surgery), podiatry, otolaryngology (ENT), gynecology (including laparoscopy), neurosurgery, orthopedics (soft tissue), arthroscopy (knee), general and thoracic surgery (including open and endoscopic), dental and oral surgery and genitourinary surgery. In addition, the Lumenis UltraPulse Encore Carbon Dioxide Surgical Lasers are safe and effective when indicated for use in specific surgical applications in medical specialties including: aesthetic (dermatology and plastic surgery), podiatry, otolaryngology (ENT), gynecology (including laparoscopy), neurosurgery, orthopedics (soft tissue), arthroscopy (knee), general and thoracic surgery (including open and endoscopic), dental and oral surgery and genitourinary surgery.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

Page updated: August 31, 2026 · How we verify

No new-unit price reference is published for this older model.

Used asking price reference
Used$25k–$55k
Source not documented

Axis runs $0–$55k. Reference figures, not current offers. Used asking prices are not completed-sale values.

Consumable cost per treatment

Not verified

We hold no per-treatment consumable price for this device from a dated source. Ask the seller for a written per-treatment cost.

Price sourcesSources, dates and configurations
Used asking range: $25k–$55k·Researched estimate — no dated source on file yet; not a quote.
Key factsCompany, specifications and verification dates
Key facts
ManufacturerLumenis
CompanyOwner: Baring Private Equity Asia (BPEA, now part of EQT) (private equity owned, since 2019) · Distribution: direct
Parent companyLumenis
Brand ownerLumenis
Built by (OEM)Lumenis Be Ltd.
CategoryCO2 Fractional/Ablative
TechnologyCO2 10600nm fractional + fully ablative (ActiveFX/DeepFX/TotalFX)
FDA statusFDA Cleared
510(k) citationK022060
New-unit reference (older model)Not published
Used asking range$25k–$55k
ConsumablesMode-dependent: ActiveFX and PigmentFX run through the reusable UltraScan CPG with no per-treatment tip, while DeepFX and DeepFX Air consume a single-use distance-gauge spacer every case (GUDID: single-use).
Launch year2006
PricingNot published
Manufacturer-source documents checkedAugust 31, 2026

Overview

Gold-standard deep CO2 with SCAAR FX scar mode

How it worksTechnology and manufacturing

How the technology works

10,600nm RF-excited CO2 with exceptionally high pulse energy (up to 225mJ), absorbed by tissue water to vaporize tissue and coagulate surrounding dermis.

ActiveFX does superficial large-spot fractional; DeepFX drives 0.12mm microspots deep for scars and rhytids; TotalFX combines both; SCAAR FX reaches depths no other aesthetic CO2 matches — why burn and trauma scar centers standardized on it.

Treats photodamage, deep wrinkles, acne and surgical scars, benign lesions — typically one-and-done with 5-10 days of downtime.

Patented technology

The UltraPulse pulse architecture — very high peak-power short pulses inherited from Coherent's surgical lineage — plus CPG pattern scanning and SCAAR FX's ultra-deep fractional mode.

Origin

Lumenis (Lumenis Be), Yokneam, Israel.

FDA & regulatory detailClearance timeline, authorization route and citation notes
Authorized via 510(k)

FDA-cleared indications (verbatim)

K022060 (Lumenis, Inc., 2002)

Lumenis UltraPulse Encore Carbon Dioxide Surgical Lasers (and their delivery accessories) are used to deliver light energy and are indicated for use in surgical applications requiring the ablation, vaporization, excision, incision, and coagulation of soft tissue in medical specialties including: aesthetic (dermatology and plastic surgery), podiatry, otolaryngology (ENT), gynecology (including laparoscopy), neurosurgery, orthopedics (soft tissue), arthroscopy (knee), general and thoracic surgery (including open and endoscopic), dental and oral surgery and genitourinary surgery. In addition, the Lumenis UltraPulse Encore Carbon Dioxide Surgical Lasers are safe and effective when indicated for use in specific surgical applications in medical specialties including: aesthetic (dermatology and plastic surgery), podiatry, otolaryngology (ENT), gynecology (including laparoscopy), neurosurgery, orthopedics (soft tissue), arthroscopy (knee), general and thoracic surgery (including open and endoscopic), dental and oral surgery and genitourinary surgery.

Verbatim from the FDA 510(k) summary, retrieved 8 Sep 2026.

Marketed for

CO2 fractional — CO2 10600nm fractional + fully ablative (ActiveFX/DeepFX/TotalFX)

Marketing claims are the manufacturer's own and are not the same as a cleared indication.

510(k) numbers

K022060

Parent company: Lumenis

Legal manufacturer: Lumenis Be Ltd. (Israel)

Applicant on the FDA record

Lumenis, Inc.The applicant named on the FDA record can differ from the brand shown on the device.

Regulatory data comes from public FDA records and may lag recent updates. Confirm the applicable status and documentation before purchase.

Treatment & running costs

Treatments

Sessions & timing

No treatment schedule documented yet.

What practices charge

No sourced treatment price on file.

Supplies & recurring costs

Mode-dependent: ActiveFX and PigmentFX run through the reusable UltraScan CPG with no per-treatment tip, while DeepFX and DeepFX Air consume a single-use distance-gauge spacer every case (GUDID: single-use).

·Used listing · Updated Aug 31, 2026

Annual service & support

No annual service cost documented yet.

Payback calculatorModel your own volume, labor and service costs

Estimate your payback

Pre-filled from our published Lumenis UltraPulse Encore data where we have it. Estimates appear once the required inputs are available. Review and adjust every pre-filled value before relying on the result.

Start from

No verified per-treatment supply cost is on file. Enter your own allowance. Use $0 only if you have confirmed that it applies to your practice.

Pre-filled from the midpoint of the published used asking range

20 is an illustrative default — change it to your volume.

No sourced per-session price on file — enter what you charge.

Required — enter your cost; missing data does not mean $0.

Provider or tech time for one treatment, fully loaded. Enter 0 if you own-operate.

Annual service contract ÷ 12, if you carry one.

Your estimate

Enter price you charge per treatment, consumable cost per treatment to see contribution and a payback range.

This model ignores financing — if you lease or borrow, add your monthly payment. Estimates from your inputs and our published ranges — not a projection, guarantee or financial advice. How we calculate this.

ComplianceScreening and contraindications on the manufacturer's record

Contraindications & screening

Isotretinoin within 6-12 months, keloid history, active infection (mandatory HSV prophylaxis perioral), Fitzpatrick IV-VI at elevated PIH/hypopigmentation risk, smokers and impaired wound healers, prior lower-lid bleph for periorbital work.

Warranty & serviceWhat to confirm in writing before you buy

Before buying new or used, confirm in writing:

  • Current warranty coverage
  • Included training
  • Service terms

Chains using this device

A chain listing does not establish availability at every location.

No confirmed chain deployments recorded yet.

Owner & operator reviews

Write a review

No owner or operator reviews yet. Be the first →

Current alternatives

Current catalog models to research. Confirm availability and configuration with the supplier.

Candela CO2RE

CO2 Fractional/Ablative · $90k–$120k

Rohrer Aesthetics Phoenix CO2

CO2 Fractional/Ablative · $59,995 (Rohrer-advertised price)

History2 tracked changes

Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.

  1. August 5, 2026

    Warranty & service

    Source: Catalog update

  2. August 1, 2026

    Record created

    Added to The Aesthetic Index — August 2026

    Source: The Aesthetic Index editorial

Cite this data: The Aesthetic Index, "Lumenis UltraPulse Encore — pricing, FDA status and cost to own", aestheticindex.co (accessed September 24, 2026).

Get the full State of Aesthetic Devices 2026 report

A catalog of US-marketed aesthetic and wellness devices — preview it free.

Get the report

Explore this model’s specs and owner reviews. For new-equipment inquiries, browse current models.

Browse current models

Device and company names are trademarks of their respective owners. The Aesthetic Index is not affiliated with or endorsed by any manufacturer, distributor or lender named here, except as disclosed. Price figures are references, not current offers. Check each device’s source notes. Not medical, legal or regulatory advice.